Search results for PX-TA1637

Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade, ProteoGenix, PX-TA1637

Description of Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade About Sotrovimab biosimilar Sotrovimab is a neutralizing monoclonal antibody with an activity against SARS-CoV-2 virus in humans. It has been commercialized as XEVUDY by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is able to bind with Spike protein, which is responsible of the pathogenicity of the Severe Acute Respiratory Syndrome- Coronavirus( SARS-CoV-2). A treatment by biosimilar recently approved FDA and EMA have very recently given their approvals for the marketing of Sotrovimab as a treatment against some severe forms of COVID. The epitope targeted by this neutralizing antibody is not mutated in the different variants of SARS-CoV-2 of concern. About Spike protein Spike glycoprotein is a transmembrane viral fusion protein. It is known to be paramount in the binding of the virus to the cell during infection process. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism. A research grade biosimilar Sotrovimab biosimilar is a dual-action antibody, which is able to to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs. Proteogenix offers this product for research use only. Sotrovimab is a human-origin monoclonal antibody expressed in a mammalian system (Chinese Hamster Ovaries-CHO).